Lexaria Biosciences Corp (NASDAQ:LEXX) Expands Its Hypertension Program Evaluating DehyfraTECH-Processed CBD’s Effectiveness

Lexaria Biosciences Corp (NASDAQ:LEXX) has announced substantial progress in its 2021 applied R&D program with more focus on the hypertension program. The hypertension program evaluating DehydrTech-processed CBD’s effectiveness will no include two animal studies and three human clinical studies.

Lexaria exp0ands its Hypertension program

Chris Bunka, the company’s CEO, said that currently, over 1.1 billion struggle with hypertension. He said that, pending completing the company’s study programs, Lexaria is planning to pursue growth opportunities through strategic partnerships with leading players in CBD pharmaceutical and hypertension marketplaces.

The 2021 Lexaria hypertension programs will not comprise five studies. Three were described in an announcement on February 1, 2021, and updated HYPER-A21, HYPER-A21-2, and HYPER-H21-1, while the two new additional studies HYPER-H21-2 and HYPER-H21-3, have been announced for the first time. The study design for the planned animal studies HYPER-A21-1 and HYPER-AQ21-2 is already complete, and formulations delivery to be tested in their labs in good condition has been confirmed. Dosing is on schedule and will begin in late February or early March.

Interestingly, HYPER-H21-1, as previously announced with the addition of HYPER-H21-2 and HYPER-H21-3, will be randomized, double-masked human clinical trials that will take place in Europe. The HYPER-H21-1 study design is already complete with approval from the ethics board and university hospital. Subject dosing will commence after shipment of clinical test articles to the site is complete, pending importation regulatory approvals.

HYPER-H21-2 study vital to Lexaria’s commercial prospects

Notably, HYPER-H21-2 was added to the hypertension program because of the increased importance on the company’s commercial prospects. The study has been designed for ambulatory blood pressure monitoring 24 hours after the dosing of subjects. Subjects will wear portable devices recording blood pressure at 30- and 60-minute intervals. Volunteers will visit the lab thrice, where they will receive DehydraTech-CBD or placebo three times daily. Study results will be vital in understanding patented DehydraTECH-processed CBD’s effectiveness as a [potential anti-hypertensive agent. The study will be complementary to short-term monitoring in HYPER-H21-1. Similarly, HYPER-H21-3 was added to the program to complement the data set Lexaria is building.